Navigation Links
Under new leadership, Kavli Institute at Cornell evolves from a think tank to a proving ground
Date:4/11/2010

ITHACA, N.Y. Looking to push the boundaries of nanoscience, the Kavli Institute at Cornell for Nanoscale Science is no longer a think tank for new ideas, but a proving ground to aggressively push the limits of nanotechnology.

And to that end, Cornell has named Paul McEuen, the Goldwin Smith Professor of Physics, as the director. David A. Muller, associate professor of applied and engineering physics, will serve as co-director.

The institute will fund projects and researchers to create and build the tools of the nanoscale future. "If you make a new tool, you can have an enormous impact in a variety of different areas. We don't have eyes and hands at the nanoscale to see and control things the way we're used to at the milli-, micro- or macro-scale," said McEuen.

The institute will focus on next-generation microscopies; physical and electronic measurement and manipulation; and optoelectronic nanocharacterization. The institute will fund small teams for development of novel instruments and two Kavli postdoctoral fellows annually.

The institute's leaders emphasize that "high-risk, high-payoff projects" will be encouraged. "We are looking for that handful of 'It's-so-crazy-it-might-actually-work' ideas that would change how we see the nanoworld," Muller said.

Other core Cornell faculty members are Dan Ralph, professor of physics, and Michal Lipson, associate professor of electrical and computer engineering.

Cornell's Kavli Institute is one of four nanoscience institutes funded by the Kavli Foundation. In fact, the 15 Kavli institutes worldwide focus on nanoscience, neuroscience, cosmology and theoretical physics. Cornell's institute has supported such activities as lectures, symposia, summer schools and workshops.

There are big thrills in pioneering into the realm of the very small. "One of the exciting things on the frontier is the development of increasingly complex nanoscale structures that have
'/>"/>

Contact: Blaine Friedlander
bpf2@cornell.edu
607-254-8093
Cornell University
Source:Eurekalert

Page: 1 2

Related biology technology :

1. Songbird genome to aid understanding of learning, memory and more
2. Matrix Corporate Capital and PharmaVentures Announce the Signing of a Memorandum of Understanding (MOU)
3. 2-Year-old Baby With Complex Heart Deformity Undergoes Major Open Heart Surgery at Wockhardt Hospitals, Bangalore - (now a Network Hospital of Fortis) Without any Blood Transfusion
4. Dendreon Announces Exercise of Option by Underwriters in its Common Stock Offering
5. Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters Over-Allotment Option
6. Understanding mechanical properties of silicon nanowires paves way for nanodevices
7. NYU-Poly Launches Unique Undergrad Forum on Invention, Innovation and Entrepreneurship
8. China Biologic Named to Forbes Magazines Fifth Annual List of Asias 200 Best Under a Billion
9. Formatech, Inc. to Donate Services to Formulate and Fill GeoVax Labs, Inc. HIV/AIDS Vaccine Under Its Fillanthropy(TM) Program
10. ISMPP Supports Best Practices and Transparency in Medical Publications: Better Understanding of Terms Such as Ghostwriting Needed
11. Booshoot Founder & CEO Jackie Heinricher Honored as Visionary Entrepreneur by Martha Stewart
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... SAN DIEGO , May 20, 2013  Dr. ... the field of nucleic acid research, recently launched a ... Zone In with Zon ( zon.trilinkbiotech.com ), focuses on ... posts include interviews with industry thought leaders, discussions of ... publications and more. Dr. Zon (PhD ...
(Date:5/20/2013)... York, NY (PRWEB) May 20, 2013 With ... Cleaning Products said that although bed bugs need to be ... process will not compromise a person's health. And so to ... guide how to get rid of bed bugs ... its non-pesticide bed bug spray it called Bed Bug Bully. ...
(Date:5/20/2013)... May 20, 2013 Cempra, Inc. (Nasdaq: ... differentiated antibiotics to meet critical medical needs in ... it presented data at the American Thoracic Society ... demonstrating the antibacterial and enhanced immunomodulatory ... Phase 2 clinical trial in outpatients with community ...
(Date:5/20/2013)... Rhythm announced today the results of a ... novel ghrelin agonist for the treatment of diabetic gastroparesis ... RM-131 significantly accelerates early gastric emptying and reduces upper ... diabetic gastroparesis. The findings were presented at the Digestive ... and recently published in Clinical Gastroenterology and ...
Breaking Biology Technology:Dr. Gerald 'Jerry' Zon Launches New Blog for TriLink BioTechnologies 2New Non Pesticide Discovery on How to Get Rid of Bed Bugs Tipped by My Cleaning Products 2Cempra Presents Post-Phase 2 Analysis of Solithromycin's Efficacy and Safety Results from Patients with Community Acquired Bacterial Pneumonia (CABP) 2Rhythm Announces Phase 1b Results for Ghrelin Prokinetic RM-131 for Gastroparesis in Patients with Type 1 Diabetes 2Rhythm Announces Phase 1b Results for Ghrelin Prokinetic RM-131 for Gastroparesis in Patients with Type 1 Diabetes 3
... ... cGMP manufacturer, announced that the company is in the initial phases of a multi-year ... Ingredient (API) manufacturing facility located in Riverview, Michigan. Expansions will include a new reactor ... ...
... , CRANBURY, N.J., Sept. 30 Amicus Therapeutics (Nasdaq: ... 1 study of AT2220 (1-deoxynojirimycin HCl), its investigational drug in ... objective of this study is to evaluate the pharmacokinetics of ... U.S. Food and Drug Administration (FDA) has agreed to Amicus, ...
... Despite a number of key issues such as ... and feed uses, global use of biofuels is excepted to ... new global analysis released today by Hart,s Global Biofuels Center. ... of total biofuels use of more than 35%. Brazil will ...
Cached Biology Technology:Ash Stevens Plans $6 Million Facility Expansion to Bolster CMC Capabilities 2Amicus Therapeutics Announces Plan to Initiate Phase 1 Study of AT2220 for Pompe Disease 2Amicus Therapeutics Announces Plan to Initiate Phase 1 Study of AT2220 for Pompe Disease 3Amicus Therapeutics Announces Plan to Initiate Phase 1 Study of AT2220 for Pompe Disease 4Global Biofuels Growth to Double by 2015 2Global Biofuels Growth to Double by 2015 3Global Biofuels Growth to Double by 2015 4
(Date:5/17/2013)... Scientists investigating the interaction of a group of proteins ... damage have identified a new target that could increase ... the University,s School of Biochemistry and published in the ... Reviews, could eventually lead to new therapies for stroke ... earlier work by the team which identified a protein, ...
(Date:5/17/2013)... MD The Federation of American Societies for Experimental ... National Institutes of Health (NIH) funding trends highlighting the ... support critical research. The FASEB analysis follows a May ... Collins, MD, PhD, who testified that the $1.6 billion ... sequestration is "having a substantial impact on the scientific ...
(Date:5/16/2013)... MD FASEB MARC (Maximizing Access to Research ... for The Society for Developmental Biology (SDB) 72nd ... 2013. These awards are meant to promote the ... groups into the mainstream of the basic science ... scientists at the SDB 2013 Annual Meeting. , ...
Breaking Biology News(10 mins):SUMO wrestling cells reveal new protective mechanism target for stroke 2
... pleased to announce an exclusive commercial license agreement ... plants and with important implications for crop improvement. ... is licensing the technology to Dow AgroSciences. Dow ... Chemical Company (NYSE: DOW), entered into an exclusive ...
... evolve for months after a traumatic brain injury (TBI), ... trauma, new research led by the University of Melbourne, ... Victorian Neurotrauma Initiative is published in the latest issue ... Around 400,000 Australians have a disability related to ...
... help from their female friends are far more successful as ... new study. , Previous research into reproductive success in animal ... benefits of inherited genetic characteristics, while others show the benefits ... uncle or other unrelated helpers. , The new ...
Cached Biology News:Dow Agrosciences licenses exclusive novel crop enhancement technology 2Study provides treatment hope for long term effects of brain trauma 2Successful mothers get help from their friends: Dolphin study 2
...
... fully licensed, high throughput, water bath thermal cycler ... 24 microplates. This equates to 9,216 reactions per ... robotic arm rapidly transfers a basket of plates ... times that are considerably faster than those of ...
anti-Yan 8B12H9...
Proliferin (N-14)...
Biology Products: